TACC3 and neoplasm: We have previously reported a partial response that lasted for 10 years in a patient with glioblastoma with CDK4 amplification and FGFR3-TACC3 chromosomal fusion, treated with bevacizumab and valproic acid, that targeted multiple pathways associated with tumor progression and angiogenesis.17